|
By HCat at 2007-02-24 10:42
|
|
   Antisoma, a London based company, announced at the ASCO Prostate Cancer Symposium positive phase II trial interim results in hormone-refractory prostate cancer patients in a combination treatment with AS1404. The results showed that PSA response rates were higher in the AS1404-docetaxel combination (57%) than with docetaxel alone (35%). Time to tumor progression and survival data will be reported later in the year, but current data shows that the frequency of PSA progression was halved in the AS1404-docetaxel combination versus docetaxel alone (17% versus 29%). Safety statistics indicate no significant increase in side-effects from AS1404.
|
|
read more | 1796 reads
|
|
By HCat at 2007-02-14 02:20
|
|
   Marshall R. Posner, MD, medical director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute in Boston reported at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO) on the randomized Phase III TAX 324 Study Group. 501 patients with locally advanced squamous cell carcinomaterm of the head and neck (SCCHN) (oral cavity, oropharynx, larynx and hypopharynx) were the focus of the study.
Â
   In the study, patients receiving docetaxel in combination with cisplatin and 5-FUterm as induction (neoadjuvant) therapy, followed by chemoradiotherapy and surgery were compared to those not receiving docetaxel. The results showed an impressive 70.6 months median overall survival in patients who took docetaxel compared to 30.1 months for those not receiving docetaxel in their treatment. There was a 30% reduction in mortality rate for those patients receiving docetaxel. There was an absolute three-year survival improvement of 14% in the docetaxel group as well. Progression-free survival (PFS) was also significantly greater with the docetaxel regimen with two-year PFS at 53% compared to 42%.
|
|
read more | 3816 reads
|
Register
